Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs InMode Ltd — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while InMode Ltd trades at $14.2 (market cap $809.93M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 15.5× InMode Ltd's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and InMode Ltd for 29 Days on average.
| HALO | INMD | |
|---|---|---|
Market Cap | $12.58B | $809.93M |
Volume | 2,179,278 | 365,490 |
Sector | Health | Health |
52-Week High | $115.22 | $16.62 |
52-Week Low | $61.63 | $12.76 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $14.49B | $313.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INMD trades at $14.14, up 0.93% on the day, with bearish technical signals from moving averages but attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 4.48. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with 76.52% gross margins. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The stock presents value opportunity with solid fundamentals but faces near-term headwinds from cyclical industry softness and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings versus 55% hold, suggesting cautious optimism amid ongoing strategic review of the acquisition proposal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
